Bard Gains Foothold In Home Care Market With Rochester Medical Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Rochester’s main products are silicone male external catheters for male urinary incontinence and silicone intermittent catheters for urinary retention, constituting a global home care urology market worth $930 million.
You may also be interested in...
Device/Diagnostics Quarterly Deal Statistics, Q3 2013
Device and diagnostics companies both suffered declines in fundraising compared with previous quarters. The biggest medtech acquisition was Stryker’s $1.4 billion buyout of MAKO, while in diagnostics BioMeriux’s $450 million purchase of BioFire topped the list.
New Products In Brief
Recent PMA approvals include Edwards Lifesciences’ Sapien transcatheter aortic heart valve expanded indication, Bolton Medical’s Relay thoracic stent graft and Paradigm Spine’s Coflex interlaminar stabilization device.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.